Clinical Trial Update: Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 single-dose dose-ranging study of olodaterol (BI 1744 CL) in chronic obstructive pulmonary disease; the trial completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Olodaterol (BI 1744 CL) (olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2014-06-30